Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children

Pediatric Pulmonology

Volumn 41, Issue 3, 2006, Pages 263-268

  Lee, Kyung Yil ^a,c   Lee, Hyung Shin ^a   Hong, Ja Hyun ^a   Lee, Mi Hee ^a   Lee, Joon Sung ^a   Burgner, David ^b   Lee, Byung Churl ^a  

^a The Catholic University of Korea   (South Korea)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c Daejeon St Mary's Hospital   (South Korea)

Author keywords

Children; Macrolides; Mycoplasma pneumoniae pneumonia; Prednisolone

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; ERYTHROMYCIN; MACROLIDE; MIOKAMYCIN; PREDNISOLONE; ROXITHROMYCIN;

ADOLESCENT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CORTICOSTEROID THERAPY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FEVER; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTOPENIA; MALE; MORBIDITY; MYCOPLASMA PNEUMONIA; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MACROLIDES; MALE; MYCOPLASMA PNEUMONIAE; PNEUMONIA, MYCOPLASMA; PREDNISOLONE; RADIOGRAPHY, THORACIC; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33644885491     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.20374     Document Type: Article

References (38)

1. Broughton RA. Infections due to Mycoplasma pneumoniae in childhood. Pediatr Infect Dis J 1986;5:71-85.
2. Ferweda A, Moll HA, de Groot R. Respiratory tract infections by Mycoplasma pneumoniae in children: a review of diagnostic and therapeutic measures. Eur J Pediatr 2001;160:483-491.
3. Waites KB. New concepts of Mycoplasma pneumoniae infections in children. Pediatr Pulmonol 2003;36:267-278.
4. Michelow IC, Olsen K, Lozano J, Rollins NK, Duffy LB, Ziegler T, Kauppila J, Leinonen M, McCracken GH Jr. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics 2004;113:701-707.
5. Hong JY, Nah SH, Man SG, Choi EW, Park JY, Lee HJ. Occurrence of Mycoplasma pneumoniae pneumonia in Seoul, Korea, from 1986-1995. J Korean Pediatr Soc 1997;40:607-613.
6. Kang KS, Woo HO. Pattern of occurrence of Mycoplasma pneumoniae pneumonia in admitted children, southern central Korea, from 1989 to 2002. J Korean Pediatr Soc 2003;46:474-479.
7. Daxboeck F, Blacky A, Seidl R, Krause R, Assadian O. Diagnosis, treatment, and prognosis of Mycoplasma pneumoniae childhood encephalitis: systematic review of 58 cases. J Child Neurol 2004;19:865-871.
8. Fernald GW. Immunologic mechanisms suggested in the association of M. pneumoniae infection and extrapulmonary disease: a review. Yale J Biol Med 1983;56:475-479.
9. Waites KB, Talkington DF. Mycoplasma pneumoniae and its role as a human pathogen. Clin Microbiol Rev 2004;17:697-728.
10. Tarp B, Jensen JS, Ostergaard L, Anderson PL. Search for agents causing atypical pneumonia in HIV-positive patients by inhibitor-controlled PCR assay. Eur Respir J 1999;13:175-179.
11. Foy HM, Ochs H, Davis SD, Kenny GE, Luce RR. Mycoplasma pneumoniae infections in patients with immunodeficiency syndromes: reports of four cases. J Infect Dis 1973;127:388-393.
12. Denny FW, Taylor-Robinson D, Allison C. The role of thymus-dependent immunity in Mycoplasma pulmonis infection of mice. J Med Microbiol 1972;5:327-336.
13. Tanaka H, Honma S, Abe S, Tamura H. Effects of IL-2 and cyclosporin A on pathologic features in mycoplasma pneumonia. Am J Respir Crit Care Med 1996;154:1908-1912.
14. Noriega ER, Simberkoff MS, Gilory FJ, Rahal JJ. Life-threatening Mycoplasma pneumoniae pneumonia. JAMA 1974; 229:1471-1472.
15. Chan ED, Welsh CH. Fulminant Mycoplasma pneumoniae pneumonia. West J Med 1995;162:133-142.
16. Radisic M, Torn A, Gutierrez P, Defranchi HA, Pardo P. Severe acute lung injury caused by Mycoplasma pneumoniae: potential role for steroid pulses in treatment. Clin Infect Dis 2000;31: 1507-1511.
17. Singer JI, DeVoe WM. Severe Mycoplasma pneumoniae infection in otherwise healthy siblings. J Pediatr 1979;95:999-1001.
18. Hutchison AA, Landau LI, Phelan PD. Severe mycoplasma pneumonia in previously healthy children. Med J Aust 1981;1: 126-128.
19. Shames JM, George RB, Holliday WB, Rasch JR, Mogabgab WJ. Comparison of antibiotics in the treatment of mycoplasma pneumonia. Arch Intern Med 1970;125:680-684.
20. Terada Y, Matsunobe S, Muro K, Go T, Chihara K, Tonomura S, Shimizu Y. Effect of hydrocortisone in severe Mycoplasma pneumoniae pneumonia. Nihon Kyobu Shikkan Gakkai Zasshi 1987;25:203-209.
21. Principi N, Esposito S. Emerging role of Mycoplasma pneumoniae and Chlamydia pneumoniae in paediatric respiratory-tract infections. Lancet Infect Dis 2001;1:334-344.
22. Layani-Milon MP, Gras I, Valette M, Luciani J, Stagnara J, Aymard M, Lina B. Incidence of upper respiratory tract Mycoplasma pneumoniae infections among outpatients in Rhone-Alpes, France, during five successive winter periods. J Clin Microbiol 1999;37:1721-1726.
23. Esposito S, Bosis S, Cavagna R, Faelli N, Begliatti E, Marchisio P, Blasi F, Bianchi C, Principi N. Characteristics of Streptococcus pneumoniae and atypical bacterial infections in children 2-5 years of age with community-acquired pneumonia. Clin Infect Dis 2002;35:1345-1352.
24. Tanaka H, Okada H, Yamagishi M, Honma S, Sugawara H, Abe S, Tamura H. Therapeutic effectiveness of prednisolone in Mycoplasma pulmonis-infected pneumonia in mice. Nihon Kyobu Shikkan Gakkai Zasshi 1994;32:42-47.
25. Biberfeld G, Sterner G. Effect of Mycoplasma pneumoniae infection on cell-mediated immunity. Infection 1976;4:17-20.
26. Sabato AR, Cooper DM, Thong YH. Transitory depression of immune function following Mycoplasma pneumoniae infection in children. Pediatr Res 1981;15:813-816.
27. Tanaka H, Koba H, Honma S, Sugaya F, Abe S. Relationships between radiological patternand cell-mediated immune response in Mycoplasma pneumoniae pneumonia. Eur Respir J 1996;9: 669-672.
28. Taylor G. Immunity to mycoplasma infections of the respiratory tract: a review. J R Soc Med 1979;72:520-526.
29. Opitz O, Pietsch K, Ehlers S, Jacobs E. Cytokine gene expression in immune mice reinfected with Mycoplasma pneumoniae: the role of T cell subsets in aggravating the inflammatory response. Immunobiology 1996-1997;196:575-587.
30. Rollins S, Colby T, Clayton F. Open lung biopsy in Mycoplasma pneumoniae pneumonia. Arch Pathol Lab Med 1986;110: 34-41.
31. Yang J, Hooper WC, Phillips DJ, Talkington DF. Cytokines in Mycoplasma pneumoniae infections. Cytokines Growth Factor Rev 2004;15:157-168.
32. MacCormik DP, Wenzel RP, Senterfit LB, Beam WE Jr. Relationship of pre-existing antibody to subsequent infection by Mycoplasma pneumoniae in adults. Infect Immun 1974;9:53-59.
33. Fine NL, Smith LR, Sheedy PF. Frequency of pleural effusions in mycoplasma and viral pneumonias. N Engl J Med 1970;283:790-793.
34. Kim BY, Lee HS, Kim IK, Choi CH, Yoo KH. Relationship between chest radiology and cold agglutinin or anti-mycoplasma antibodies in Mycoplasma pneumoniae pneumonia. J Korean Pediatr Soc 1993;36:959-966.
35. Fernald GW, Collier AM, Clyde WA Jr. Respiratory infections due to Mycoplasma pneumoniae in infants and children. Pediatrics 1975;55:327-335.
36. Kim CK, Chung CY, Kim JS, Kim WS, Park Y, Koh YY. Late abnormal findings on high-resolution computed tomography after mycoplasma pneumonia. Pediatrics 2000;105:372-378.
37. Stokes D, Sigler A, Khouri NF, Talamo RC. Unilateral hyperlucent lung (Swyer-James syndrome) after severe Mycoplasma pneumoniae infection. Am Rev Respir Dis 1978;117: 145-152.
38. McGowan JE Jr, Chesney PJ, Crossley KB, LaForce FM. Guidelines for the use of systemic glucocorticosteroids in the management of selected infections. J Infect Dis 1992;165:1-13.